Elevation in Inflammatory Serum Biomarkers Predicts Response to Trastuzumab-Containing Therapy
Figure 2
Serum ferritin and CRP predict response to trastuzumab-containing therapy.
Pre-treatment serum ferritin and CRP predict overall survival (A&C respectively) and progression-free survival (PFS; B&D respectively) in patients receiving trastuzumab-containing therapy. Low serum ferritin or CRP (<250 ng/ml and <7.25 mg/l respectively) had an overall better clinical outcome than high ferritin or CRP. Difference in OS and PFS were analyzed by Kaplan-Meier survival model with the median serum ferritin or CRP value as a cutoff point.